Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals, Inc. at the 2018 Cantor Global Healthcare Conference  (Replay)
    Wednesday, October 03, 2018 11:30 am EDT
Toggle Summary Spring Bank Announces Inarigivir Data Presentations at AASLD Conference
HOPKINTON, Mass. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will present
Toggle Summary Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
HOPKINTON, Mass. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors
Former Celgene President & COO Joins Spring Bank Board HOPKINTON, Mass. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and
Toggle Summary Spring Bank Announces Pricing of Public Offering of Common Stock
HOPKINTON, Mass. and NEW YORK , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $12.50 per share, for expected gross proceeds of
Toggle Summary Spring Bank Announces Proposed Public Offering of Common Stock
HOPKINTON, Mass. and NEW YORK , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the
Toggle Summary Spring Bank Announces Positive Study Results from the Inarigivir ACHIEVE Trial
Maximum Reduction in HBV DNA up to 2.76log 10 and HBV RNA up to 5.0log 10 28% of Inarigivir Treated Patients Demonstrate a HBsAg Response with a Mean Reduction of 0.8log 10 and a Maximum Reduction of 1.4log 10 in Cohorts 1-3 of ACHIEVE Trial Two Additional Cohorts Added to HBV Clinical Program for
Toggle Summary Spring Bank Pharmaceuticals Reports Second Quarter Financial Results
Conference Call Scheduled for Thursday, August 2 at 8:00 a.m. EDT to Provide Corporate Update HOPKINTON, Mass. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral
Toggle Summary Spring Bank to Present at Jefferies 2018 Global Healthcare Conference
HOPKINTON, Mass. , May 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results
Presented inarigivir 25 mg and 50mg cohorts from Phase 2 ACHIEVE trial in chronic hepatitis B patients at two scientific conferences Continues to advance SB 11285, a next-generation STING agonist, towards clinical trial HOPKINTON, Mass. , April 27, 2018 (GLOBE NEWSWIRE) -- Spring Bank
Toggle Summary Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations *30% of patients in first two cohorts achieved >0.5log 10 reduction in HBsAg *Additional benefit of >0.5log 10 reduction